Navigation Links
GeneNews selected to present late-breaking abstract at AACR Annual Meeting
Date:3/17/2008

-Abstract describes six-gene biomarker panel for assessment of current risk

for colorectal cancer-

TORONTO, March 17 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing molecular diagnostic tests derived from a simple blood sample for the early detection of diseases and personalized health management, today announced that its abstract describing the performance of the Company's six-gene biomarker panel for the assessment of a person's current risk for colorectal cancer from a blood sample, has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California. The abstract is entitled "Stratification of colorectal cancer probability using six genes from whole blood."

"This six gene biomarker set will form the basis of a laboratory developed test (LDT) version of ColonSentry(TM), which we expect to launch in the third quarter of 2008 through our in-house clinical reference lab located in the Toronto-area," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "We are pleased that AACR has chosen to accept our abstract given the limited number of late-breaking submissions that are accepted and believe that this acceptance also represents further peer-reviewed validation of our proprietary Sentinel Principle technology."

The following GeneNews abstract will be presented:

Abstract Number LB-214:

"Stratification of colorectal cancer probability using six genes from whole blood." Clinical Research 2, Poster Section 19, Tuesday, April 15, 2008, 8:00 AM

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry, is a convenient and patient-friendly blood-based biomarker test that can identify the current risk of colorectal cancer. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews receives ISO 13485 accreditation
2. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
7. New Technology for Early Detection of Lung Cancer Selected for Clinical Study With Veterans
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. CYIG Awarded Chinas "Top 100 Enterprises" in New Pharmaceuticals, Selected as National "Torch Plan Key High-Tech Enterprise"
10. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
11. Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Mass. , Feb. 17, 2017  If ... small tumor had a mutation-conferring resistance to chemotherapy, ... Recently, genomics research has focused on finding these ... or even from circulating tumor DNA in blood ... new oncology therapeutics. Unfortunately, however, detecting ...
(Date:2/16/2017)... , Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... system to find a better treatment for triple negative breast ... in France program. The ... an accelerator designed to help entrepreneurs grow their business in ... one of eight American companies selected to complete an intensive ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
Breaking Biology Technology:
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
Breaking Biology News(10 mins):